Developing global, high-value products for patients with significant unmet medical needs in niche indications
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
IPO Calliditas Therapeutics
On November 1, 2018, Calliditas Therapeutics published its interim report for the third quarter of 2018.
Calliditas Therapeutics AB
SE-111 24 Stockholm
Company number: 556659-9766
© Calliditas Therapeutics AB 2018